Regimen Reference Order – GAST – ramucirumab + PACLitaxel

ARIA: GAST – [ramucirumab + PACLitaxel]

Planned Course: Every 28 days until disease progression or unacceptable toxicity
Indication for Use: Gastric cancer metastatic or gastro-esophageal junction adenocarcinoma

CVAD: At Provider's Discretion

Proceed with treatment if:

Day 1

- ***ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L***
- ***Total bilirubin equal or less than 1.5 times upper limit of normal***
- ***AST and ALT equal or less than 3 times upper limit of normal if no liver metastases***
- ***AST and ALT equal or less than 5 times upper limit of normal if liver metastases***

Days 8 and 15

- ***ANC equal to or greater than 1 X 10^9/L AND Platelets equal to or greater than 75 X 10^9/L***
- ***Total bilirubin equal or less than 1.5 times upper limit of normal***
- ***AST and ALT equal or less than 3 times upper limit of normal if no liver metastases***
- ***AST and ALT equal or less than 5 times upper limit of normal if liver metastases***
  - ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GAST – ramucirumab + PACLitaxel

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Days 1 and 15		
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes prior to ramucirumab
raNITIdine	50 mg	IV in normal saline 50 mL over 15 minutes prior to ramucirumab
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes prior to ramucirumab
acetaminophen	650 mg	Orally prior to ramucirumab as needed. *If patient has had a previous Grade 1 to 2 hypersensitivity reaction
ramucirumab	8 mg/kg	IV in normal saline 250 mL over 60 minutes Use 0.22 micron in-line filter
metoclopramide	20 mg	Orally prior to PACLitaxel

PACLitaxel	80 mg/m2	IV in normal saline 250 mL over 60 minutes *Use non-DEHP bags and non-DEHP administration sets with 0.22 micron in-line filter*
Day 8		
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes prior to PACLitaxel
raNITIdine	50 mg	IV in normal saline 50 mL over 15 minutes prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes prior to PACLitaxel
acetaminophen	650 mg	Orally prior to PACLitaxel as needed. *If patient has had a previous Grade 1 to 2 hypersensitivity reaction
metoclopramide	20 mg	Orally prior to PACLitaxel
PACLitaxel	80 mg/m^2	IV in normal saline 250 mL over 60 minutes *Use non-DEHP bags and non-DEHP administration sets with 0.22 micron in-line filter*
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See GAST DSG – Dose Banding document for more information		

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

- Observe patient for 1 hour post-ramucirumab infusion with first and second ramucirumab infusions and then 30 minutes with subsequent ramucirumab infusions
- Blood pressure to be taken prior to every dose of ramucirumab (hypertension with ramucirumab)
- CBC, BUN, serum creatinine, total bilirubin, AST, ALT prior to days 1, 8 and 15 of each cycle
- Urinalysis for protein. Where urinalysis is not possible, use dipstick. If lab urinalysis for protein is greater than or equal to 1g/L or dipstick proteinuria shows 2+ or 3+, notify medical oncologist
    - To be done prior to each dose of ramucirumab
- TSH prior to Day 1 of each cycle

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 - 6 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Inform patient of delayed infusion type reactions: chills, flushing, hypotension, bronchospasm, dyspnea, hypoxia
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Response will be determined by CT scans every 2 cycles (8 weeks)